Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan versus urea for inpatient hypotonic hyponatraemia
ACTRN12624000756527Phase 3Recruiting
- Sponsor
- University of Melbourne
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hyponatraemia comparing Tolvaptan with Urea (2 arms). Primary endpoint: Change in serum sodium over time. Started Apr 2026; status: recruiting.
02
Drugs
tolvaptanurea
03
Conditions
hyponatraemia
Beyond the preview
Go deeper on ACTRN12624000756527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000756527.